Assenagon Asset Management S.A. Sells 306,317 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Assenagon Asset Management S.A. lowered its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 19.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,264,956 shares of the medical equipment provider's stock after selling 306,317 shares during the period. Intuitive Surgical comprises about 1.0% of Assenagon Asset Management S.A.'s investment portfolio, making the stock its 12th biggest holding. Assenagon Asset Management S.A. owned approximately 0.36% of Intuitive Surgical worth $626,495,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ISRG. Norges Bank purchased a new stake in Intuitive Surgical during the 4th quarter valued at $2,401,493,000. GAMMA Investing LLC boosted its position in Intuitive Surgical by 54,010.7% during the 1st quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock valued at $14,999,630,000 after buying an additional 3,022,979 shares during the period. Proficio Capital Partners LLC boosted its position in Intuitive Surgical by 89,098.8% during the 4th quarter. Proficio Capital Partners LLC now owns 949,967 shares of the medical equipment provider's stock valued at $495,845,000 after buying an additional 948,902 shares during the period. Capital Research Global Investors boosted its position in Intuitive Surgical by 25.5% during the 4th quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider's stock valued at $1,764,904,000 after buying an additional 687,906 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Intuitive Surgical during the 4th quarter valued at $313,769,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

ISRG stock traded down $9.41 during mid-day trading on Thursday, reaching $513.00. 2,390,381 shares of the stock traded hands, compared to its average volume of 1,668,728. Intuitive Surgical, Inc. has a one year low of $413.82 and a one year high of $616.00. The stock has a market capitalization of $183.87 billion, a PE ratio of 80.03, a PEG ratio of 5.85 and a beta of 1.67. The business has a 50-day moving average price of $525.48 and a two-hundred day moving average price of $538.67.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. The business had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. During the same quarter in the previous year, the business posted $1.50 earnings per share. On average, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Robert Desantis sold 188 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the completion of the sale, the executive vice president now directly owns 5,224 shares of the company's stock, valued at approximately $2,695,113.84. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mark Brosius sold 215 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $549.06, for a total transaction of $118,047.90. Following the sale, the senior vice president now directly owns 1,768 shares of the company's stock, valued at $970,738.08. This represents a 10.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,998 shares of company stock worth $2,611,577 over the last quarter. Insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on ISRG shares. Evercore ISI decreased their price objective on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a report on Wednesday, April 23rd. Royal Bank of Canada decreased their price objective on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Barclays decreased their price objective on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Deutsche Bank Aktiengesellschaft lowered shares of Intuitive Surgical from a "hold" rating to a "sell" rating and decreased their price objective for the stock from $515.00 to $440.00 in a report on Monday. Finally, Piper Sandler decreased their price objective on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $588.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.